JaLCDOI 10.18926/AMO/56183
FullText URL 72_4_427.pdf
Author Sekimizu, Masahiro| Fujimoto, Junichiro| Takimoto, Tetsuya| Tsurusawa, Masahito| Horibe, Keizo| Sunami, Shosuke|
Abstract Pediatric patients with lymphoblastic lymphoma are generally treated using the Berlin-Frankfurt-Munster (BFM) 90 protocol, which is the standard treatment strategy for pediatric acute lymphoblastic leukemia, and have a favorable outcome. However, this intense regimen includes high total doses of anthracycline and alkylating agents, and is known to cause late complications. We therefore planned a clinical trial to examine the efficacy and safety of a modified BFM regimen. We expect that this phase II, nationwide multicenter trial will help to establish an effective and safer standard therapy for stage I/II pediatric lymphoblastic lymphoma.
Keywords pediatrics limited stage lymphoblastic lymphoma efficacy safety
Amo Type Clinical Study Protocol
Published Date 2018-08
Publication Title Acta Medica Okayama
Volume volume72
Issue issue4
Publisher Okayama University Medical School
Start Page 427
End Page 430
ISSN 0386-300X
NCID AA00508441
Content Type Journal Article
language 英語
Copyright Holders CopyrightⒸ 2018 by Okayama University Medical School
File Version publisher
Refereed True
PubMed ID 30140093